Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:41 2024-05-07 am EDT 		5-day change 1st Jan Change
34.2 DKK +1.97% Intraday chart for H. Lundbeck A/S +0.47% +4.40%
Apr. 09 H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Apr. 09 Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
AQ
Lundbeck : Articles of Association
PU
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
AQ
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office
AQ
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage
AQ
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders
AQ
Notice of Annual General Meeting
AQ
Lundbeck announces changes to Executive Management
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. News H. Lundbeck A/S
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW